PETRI DISH PERSPECTIVES

October 2026: Biotech & Pharma NEWS Roundup

Описание

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026!

This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled the GLP-1 race, and M&A activity that shows Big Pharma is quietly pivoting away from oncology toward rare disease, pain, and RNA therapeutics. The FDA approved dostarlimab in locally advanced rectal cancer, tucatinib in HER2-positive breast cancer, and talazoparib plus enzalutamide in metastatic prostate cancer — three meaningful wins for patients in a single month. Lilly’s retatrutide beat Ozempic head-to-head with 20.9% weight loss in diabetic patients, cementing its status as the next major GLP-1 contender. On the deal front, Shionogi paid $2 billion for IntraBio in rare neurodegeneration, Viatris acquired Pacira BioSciences for $1.65 billion in non-opioid pain, and Merck KGaA bought Silence Therapeutics at a 130% premium — six deals totaling over $7 billion for the month. VC finished strong with Formation Bio raising $600 million to buy drug candidates and Dren Bio closing $350 million, part of over $1.4 billion in rounds in the final week alone. And HHS greenlighted six experimental peptides over the open objections of FDA career scientists — a regulatory move that signals growing tension between evidence standards and the current policy posture. The bigger story: capital is flowing, but it’s getting selective — and the therapeutic areas winning M&A attention this month tell you exactly where the smart money thinks the next decade of returns will come from.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Комментарии

Комментариев пока нет — напишите первый.